Unknown statusInterventionalNot ApplicableLast updated Jan 11, 2021

Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity

Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity: A Randomized Controlled Clinical Trial

Overview

ClinicalTrials.gov ID: NCT04702906
Lead Sponsor: Tanta UniversityOTHER
Brief Summary: The aim of the present study is to evaluate the potential adjuvant therapeutic effect of trimetazidine in treatment of acute AlP poisoning-induced cardiotoxicity.
Study Type: Interventional

Status

Study Record Dates

NCT04465539Completed

The Potential Therapeutic Role of Hydroxyethyl Starch and Hydrocortisone in Acute Aluminum Phosphide Poisoning

NCT03879356Completed

Supportive Measures in Treatment of Aluminum Phosphide Poisoning

NCT02760823Unknown status

Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning

NCT04509258Unknown status

Effectiveness of N-acetyl Cysteine, Acetyl L- Carnitine and Medicated Paraffin Oil in Aluminium Phosphide Poisoning

NCT04191265Unknown status

Cardiotoxicity of Aluminum Phosphide Poisoning; Tropinin and CKmb as Early Biomarkers

NCT03953248Completed

L-Carnitine as an Adjuvant Treatment in Acute Phosphide Poisoning (LC)